Abstract: SA-OR39
Effect of a Nutritional Supplement of Probiotics and/or Prebiotics vs. Placebo on Nutritional Status in Automated Peritoneal Dialysis (APD) Patients
Session Information
- High-Impact CKD Potpourri: Something for Everyone
November 05, 2022 | Location: W307, Orange County Convention Center‚ West Building
Abstract Time: 05:42 PM - 05:51 PM
Category: Health Maintenance‚ Nutrition‚ and Metabolism
- 1400 Health Maintenance‚ Nutrition‚ and Metabolism
Authors
- Martin del Campo, Fabiola, Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
- Cueto-Manzano, Alfonso M., Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
- Sanchez-Ramirez, Carmen, Universidad de Colima Facultad de Medicina, Colima, Colima, Mexico
- Vega, Natali, Departamento de Microbiología y Patología, Universidad de Guadalajara, Guadalajara, Mexico
- Peña Rodríguez, Marcela, Universidad de Guadalajara Departamento de Biologia Molecular y Genomica, Guadalajara, Jalisco, Mexico
- Cortes-Sanabria, Laura, Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
- Rojas-Campos, Enrique, Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
- Villasana Ballesteros, Mariana, Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
Group or Team Name
- Unidad de Investigación Médica en Enfermedades Renales
Background
Prebiotics and probiotics may improve nutritional status in dialysis patients by decreasing inflammation and intestinal production of uremic toxins; however, no study has been performed comparing these interventions altogether and separately. Aim: to evaluate the effect of a supplement of probiotics and/or prebiotics vs placebo on nutritional status in APD.
Methods
Randomized, triple blinded, controlled, clinical trial in 64 clinically stable APD patients, assigned to: Probiotic (2x108 CFU probiotics+placebo); Prebiotic (20g inulin+placebo); Simbiotic (2x108 CFU probiotics+20g inulin); or Placebo (placebo+placebo) during 3 months. Nutritional status determined by subjective global assessment (SGA). Intestinal microbiota was evaluated with 16S rRNA gene sequency.
Results
Nutritional status results shown in Figure. Prebiotic group increased SGA score (5.1±1.1 vs 5.9±0.7, p=0.02), dietary intake of energy (1121±373 vs 1508±637, p=0.02) and marginally fiber (17±7 vs 24±12, p=0.08); Probiotic marginally increase SGA (5.6±1.0 vs 6.1±0.7, p=0.06); no statistical differences were observed in Symbiotic and Placebo groups. At the end of the study, Prebiotic significantly increased relative abundance of Blautia, Ruminococcaceae and Faecalibacterium prausnitzii bacteria and decreased Clostridiales; compared to placebo, Prebiotic showed higher predominance of Succinivibrio, Aeromonadales, Bifidobacterium, Bifidobacteriales and SMB53 at final evaluation.
Adherence to treatment was >90% in all groups during the study; main adverse effects were mild gastrointestinal symptoms (not significantly different between groups).
Conclusion
Prebiotic improve nutritional status and intestinal microbiota in APD patients; this could be an easy and inexpensive intervention for this patients.